Immunosuppressive and monoclonal antibody treatment for myasthenia gravis: A network meta‐analysis

Abstract

These findings demonstrated that ECZ represented the most effective and tolerable therapeutic alternative to be recommended for refractory MG. TAC may be a beneficial therapy to treat MG extensively while the efficacy of CsA and cyclophosphamide may be limited by their multiple or severe AEs.